Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors-Reference-Cited by-同舟云学术

Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors

Published:2019-03-13 Issue:5 Volume:94 Page:563-574
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Leaf Rebecca Karp¹^ORCID,Ferreri Christopher²,Rangachari Deepa³,Mier James³,Witteles Wesley⁴,Ansstas George⁵,Anagnostou Theodora⁶,Zubiri Leyre¹,Piotrowska Zofia¹,Oo Thein H.⁷^ORCID,Iberri David⁸^ORCID,Yarchoan Mark⁹,Salama April K. S.¹⁰,Johnson Douglas B.¹¹,Leavitt Andrew D.¹²,Rahma Osama E.¹³,Reynolds Kerry L.¹,Leaf David E.¹⁴^ORCID

Affiliation:

1. Division of HematologyMassachusetts General Hospital Boston Massachusetts

2. Department of Internal MedicineDuke University Hospital Durham North Carolina

3. Division of Hematology and OncologyBeth Israel Deaconess Medical Center Boston Massachusetts

4. Divison of Hematology and OncologyVA Palo Alto Health Care System Palo Alto California

5. Division of Hematology and OncologyWashington University St. Louis St. Louis Missouri

6. Division of Medical OncologyMayo Clinic Rochester Minnesota

7. Section of Benign HematologyUniversity of Texas M.D. Anderson Cancer Center Houston Texas

8. Division of HematologyStanford University Medical Center Stanford California

9. Division of OncologyJohns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore Maryland

10. Division of Medical OncologyDuke University Hospital Durham North Carolina

11. Department of MedicineVanderbilt University Medical Center Nashville Tennessee

12. Division of Hematology and OncologyUniversity of California San Francisco San Francisco California

13. Division of Medical OncologyBrigham and Women's Hospital and Dana Farber Cancer Institute Boston Massachusetts

14. Division of Renal MedicineBrigham and Women's Hospital Boston Massachusetts

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25448

Reference47 articles.

1. Immune Checkpoint Blockade in Cancer Therapy

2. Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4

3. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

5. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rare Immune-Related Adverse Events (irAEs): Approach to Diagnosis and Management;Pharmaceutical Medicine;2024-01

2. Checkpoint inhibitors;Hematology;2023-12-08

3. Novel pharmacotherapy for drug-induced immune hemolytic anemia;Expert Opinion on Pharmacotherapy;2023-12-06

4. Delayed cold-type autoimmune hemolytic anemia responding to Rituximab in a melanoma patient treated with Ipilimumab and Nivolumab;European Journal of Cancer;2023-11

5. The Role of the Spleen and the Place of Splenectomy in Autoimmune Hemolytic Anemia—A Review of Current Knowledge;Diagnostics;2023-09-09